Biocodex
Privately held: no public share price
Assets
(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
4Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Approved | GABA-A receptorSmall molecule | EpilepsyPrimary HyperoxaluriaDevelopmental and Epileptic EncephalopathiesDravet Syndrome Primary Hyperoxaluria Type 1 |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2030 (1)
August 2030 (1)
StiripentolPhase 3Primary Hyperoxaluria Type 1, Primary Hyperoxaluria Type 2, Primary Hyperoxaluria Type 3
Est. primary completion 2030-08 · NCT06465472 · CT.gov ↗
What to watch
Financial reports
No financial reports recorded.